MedTrace Logo

ObServatory Children Acute RElated Therapy Leukemia

NCT04450784 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-07-01

No results posted yet for this study

Summary

Acute Myeloid Leukemias (AML) of the child are a rare disease and its prognosis varies according to the subgroup. Secondary AMLs remain a subgroup of poor prognosis, whose cytogenetic and molecular characteristics and prognostic value differ in part from de novo AMLs. The purpose of this national observatory is to record scientific and medical information on cases of secondary AML that have occurred in France since 2013 in order to improve the treatment of children and adolescents with this disease in the years to come. This national observatory will contribute to better knowledge and progress in research into these diseases.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

OTHER

collection of the clinical and biological characteristics of secondary AMLs in children

to record scientific and medical information on cases of secondary Acute Myeloid Leukemias that have occurred in France since 2013

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2024-09-01
Completion
2024-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04450784 on ClinicalTrials.gov